Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway ...
This is a preview. Log in through your library . Abstract Proinflammatory responses induced by Toll-like receptors (TLRs) are dependent on the activation of the NF-ĸB and mitogen-activated protein ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback